Since GOF mutant p53 accumulation is important for its oncogenic activities and survival of the cancer cells, we hypothesized that the observed phenomenon of GOF p53 degradation by proteasome inhibitors could have functional implications for their therapeutic use in GOF p53 mutant NSCLC. The gene discussed is TP53; the disease is non-small cell lung carcinoma.